detected by performing polymerase chain reaction (PCR) with oligonucleotides flanking the repetitive sequence (upstream primer: 5'-CTCAGCAGGGAAACAGGACTG-3'; downstream primer: 5'-GTTTGAGCCACTGCACTCAGC-3'). PCR amplification of HSIi6[CA] n produced 228-246 bp DNA fragments. Eight Centre d'Etude Polymorphisme Humain (CEPH) reference families (102, 884,1331, 1332,1347, 1362, 1413, and 1416) and French Caucasian unrelated individuals were genotyped for HSLA6 [CA] n following a multiplexing procedure (5) . Eleven different alleles were found among 80 unrelated individuals with a heterozygosity (HET) of 0.75. Mendelian inheritance was confirmed in the eight CEPH families studied.
To map LIPE, a two-point linkage analysis was performed between HSIi6[CA] n and markers from Genethon (6) using version 5.2 of the LINKAGE package of computer programs (7) . Based on segregation analysis in the eight CEPH pedigrees, LIPE was mapped on chromosome 19 in the interval between AFM238wf 10 and AFMal31wf5 with recombination fractions (6) of 0.043 and 0.016, and logarithm of odds (LOD) scores of 24.76 and 29.57, respectively. Multipoint analysis allowed us to determine the location of LIPE, relative to close microsatellites in the following order:
cen-AFM238wflO(9 = 0.013)-AFMal97xa5(6 = 0.006)-LIPE-(9 = 0.004)AFM126zcl-(6 = 0.001)AFMal31wf5-(8 = 0.001)AFM326xh9-tel. This most likely order was supported by odds of 1,000:1 against any permutation of two adjacent markers. Therefore, LIPE is located within the 1-cM interval flanked by AFMal97xa5 (D19S872) and AFM126zcl (D19S211) at a distance of 0.6 and 0.4 cM, respectively.
Haplotype analysis was performed on grandparents or parents in the CEPH families with HSIi6[CA] n and the previously reported dinucleotide repeat located in the seventh intron (4), these polymorphisms being separated by a physical distance of -2,800 bp. We identified nine alleles for HSIi6 Data are percentages of alleles. Alleles are listed in order of size (alleles-bis are rare size-intermediates). NIDDM-IGT group corresponds to the pool of patients with diabetes or IGT. n indicates the number of chromosomes sampled. For the comparison with the lean controls, the rare alleles with frequencies <5% (1, Ibis, 2, 2bis, 3bis, 6bis, 8,10, and 11) were pooled into a single categoiy; thus the x 2 for the overall distribution have 6 df. Because of the significant differences observed, the role of allele 5 in excess was evaluated by x 2 with 1 df (*P < 0.05, fP < 0.02).
NIDDM and IGT were diagnosed by World Health Organization criteria. Lean and obese subjects were classified according to a BMI <25 and >27 kg/m 2 , respectively. We studied 75 healthy lean control subjects with no history of diabetes (38 women, 38 men* age range 26-69 years; mean age 44 years; BMI 22 ± 2 kg/m Comparison of control and patient groups was performed using x 2 tests. The nine rare alleles, i.e., with frequencies <5% (alleles 1, Ibis, 2, 2bis, 3bis, 6bis, 8, 10, and 11), were pooled into a single category to ensure the validity of the x 2 test, thus resulting in a marker of seven alleles. The allele distribution differed between the patient groups and the control group (Table 1) . The association with obesity that was observed with the obese normoglycemic group was strengthened when the obese patients, either diabetic or not, were pooled and compared with lean control subjects (x 2 = 20.4, P = 0.002 with 6 df; data not shown). Also, when the IGT and NIDDM groups that presented similar allelic distributions were pooled, the difference from the control group was more significant (P = 0.005, Table 1 ). Therefore, the HSLi6[CA] n allelic distribution was altered in obesity and diabetes.
The differences observed in the allelic distribution were essentially due to a significant increase in the frequency of allele 5 in the obese and NIDDM-IGT groups as compared with the control subjects (obese nondiabetic patients x 2 = 6, P < 0.02; NIDDM-IGT patients x 2 = 5.9, P < 0.02 with 1 df). The relative risk conferred by the presence of allele 5, estimated by the odds ratio, was 1.92 (95% CI 1.4-2.44) for obese patients and 1.62 (95% CI 1.23-2) for NIDDM-IGT patients. Interestingly, the prevalence of homozygotes for allele 5 was increased in patient groups since we found 37% of obese subjects homozygous for this allele as compared with 12% of lean subjects (x 2 = 10.5, P = 0.001). An increased frequency of homozygotes was observed in the group of NIDDM-IGT patients either obese (31%, x 2 = 7.7, P < 0.01) or lean (26%, x 2 = 4.6, P < 0.05), indicating that the association of allele 5 with diabetes occurs independently of obesity. When allele 5 was removed, the distribution of the remaining alleles was still altered in the NIDDM-IGT group (x 2 = 10.8, P < 0.03), while not in the obese group. This was mainly due to an increased frequency of the rare alleles. However, due to their low frequency, their individual contribution could not be evaluated in our population.
Our data show that the HSLi6[CA] n microsatellite is associated with obesity and with NIDDM, suggesting that HSL could represent a susceptibility gene for both disorders. Although studies in other populations are required, our data suggest that variants of the HSL gene may present some altered function or expression. The characterization of a novel polymorphism in the HSL gene coupled with its localization relative to other highly polymorphic flanking markers should prove useful for familial genetic analysis in obesity, NIDDM, and related disorders.
